| Primary |
| Breast Cancer |
34.7% |
| Multiple Myeloma |
6.1% |
| Non-hodgkin's Lymphoma |
5.3% |
| Chronic Lymphocytic Leukaemia |
5.2% |
| Premedication |
4.6% |
| Product Used For Unknown Indication |
4.3% |
| Pain |
3.9% |
| Hypertension |
3.7% |
| B-cell Lymphoma |
3.6% |
| Diffuse Large B-cell Lymphoma |
3.6% |
| Prophylaxis |
3.6% |
| Lymphoma |
3.4% |
| Plasma Cell Myeloma |
2.8% |
| Breast Cancer Metastatic |
2.7% |
| Chemotherapy |
2.4% |
| Nausea |
2.4% |
| Multiple Sclerosis |
2.2% |
| Prostate Cancer |
2.2% |
| Drug Use For Unknown Indication |
1.8% |
| Insomnia |
1.8% |
|
| Vomiting |
13.9% |
| Febrile Neutropenia |
9.4% |
| Dehydration |
6.7% |
| Pyrexia |
6.7% |
| Neutropenia |
6.1% |
| Thrombocytopenia |
6.1% |
| Pancytopenia |
5.6% |
| Pneumonia |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Sepsis |
4.4% |
| Dyspnoea |
3.9% |
| Hypersensitivity |
3.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.9% |
| Death |
3.3% |
| Alopecia |
2.8% |
| Infection |
2.8% |
| Malignant Neoplasm Progression |
2.8% |
| Nausea |
2.8% |
| Renal Failure Acute |
2.8% |
| Cellulitis |
2.2% |
|
| Secondary |
| Breast Cancer |
22.4% |
| Drug Use For Unknown Indication |
13.6% |
| Product Used For Unknown Indication |
12.9% |
| Behcet's Syndrome |
12.5% |
| Chronic Lymphocytic Leukaemia |
7.6% |
| Multiple Myeloma |
5.6% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Diffuse Large B-cell Lymphoma |
2.9% |
| Non-hodgkin's Lymphoma |
2.6% |
| B-cell Lymphoma |
2.2% |
| Pain |
1.9% |
| Breast Cancer Metastatic |
1.7% |
| Hodgkin's Disease |
1.7% |
| Plasma Cell Myeloma |
1.4% |
| Multiple Sclerosis |
1.4% |
| Premedication |
1.4% |
| Chemotherapy |
1.4% |
| Vasculitis |
1.3% |
| Hypertension |
1.3% |
| Amyloidosis |
1.2% |
|
| Vomiting |
11.3% |
| Febrile Neutropenia |
9.4% |
| Pyrexia |
9.4% |
| Squamous Cell Carcinoma Of Skin |
8.2% |
| Sepsis |
7.2% |
| Skin Cancer |
6.3% |
| Thrombocytopenia |
5.6% |
| White Blood Cell Count Decreased |
4.7% |
| Tachycardia |
4.1% |
| Respiratory Failure |
3.8% |
| Pneumonitis |
3.4% |
| Nausea |
3.1% |
| Pleural Effusion |
3.1% |
| Progressive Multifocal Leukoencephalopathy |
3.1% |
| Squamous Cell Carcinoma |
3.1% |
| Dyspnoea |
2.8% |
| Hypoaesthesia |
2.8% |
| Neutropenia |
2.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.8% |
| Pneumonia |
2.8% |
|
| Concomitant |
| Breast Cancer |
14.4% |
| Drug Use For Unknown Indication |
13.2% |
| Product Used For Unknown Indication |
12.7% |
| Multiple Myeloma |
11.4% |
| Metastases To Bone |
7.3% |
| Chemotherapy |
6.9% |
| Pain |
5.4% |
| Breast Cancer Metastatic |
4.5% |
| Depression |
3.2% |
| Multiple Sclerosis |
2.8% |
| Nuclear Magnetic Resonance Imaging |
2.7% |
| Osteoporosis |
2.5% |
| Prophylaxis |
1.9% |
| Nausea |
1.8% |
| Hypertension |
1.7% |
| Chronic Lymphocytic Leukaemia |
1.6% |
| Anxiety |
1.6% |
| Premedication |
1.5% |
| Non-hodgkin's Lymphoma |
1.5% |
| Systemic Lupus Erythematosus |
1.5% |
|
| Weight Decreased |
15.7% |
| Weight Increased |
8.0% |
| Wound Drainage |
7.7% |
| Vomiting |
7.3% |
| Tooth Extraction |
6.4% |
| Pyrexia |
5.2% |
| Wheezing |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Death |
4.9% |
| White Blood Cell Count Increased |
3.6% |
| Wound Infection Staphylococcal |
3.6% |
| Thrombocytopenia |
3.5% |
| Urticaria |
3.2% |
| Drug Ineffective |
3.1% |
| Neutropenia |
3.1% |
| Vision Blurred |
3.1% |
| Wound Secretion |
3.1% |
| Febrile Neutropenia |
3.0% |
| Rash |
2.7% |
| Sepsis |
2.7% |
|
| Interacting |
| Prophylaxis Of Nausea And Vomiting |
100.0% |
|
| Infusion Site Phlebitis |
50.0% |
| Middle Insomnia |
50.0% |
|
